奥克雷珠单抗--我们所知道的、现在可以改进的、未来可以改进的

{"title":"奥克雷珠单抗--我们所知道的、现在可以改进的、未来可以改进的","authors":"M. Elišák","doi":"10.36290/neu.2024.008","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":502927,"journal":{"name":"Neurologie pro praxi","volume":"80 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ocrelizumab - what we know, what we can improve now, what we can improve in the future\",\"authors\":\"M. Elišák\",\"doi\":\"10.36290/neu.2024.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":502927,\"journal\":{\"name\":\"Neurologie pro praxi\",\"volume\":\"80 8\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurologie pro praxi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36290/neu.2024.008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurologie pro praxi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36290/neu.2024.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}